Trial Profile

A combination study of Deep IL-12 and Deep IL-15 Primed T cells

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 18 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TRQ 1201 (Primary) ; TRQ 1501 (Primary)
Indications Haematological malignancies; Solid tumours
Focus Adverse reactions
Sponsors Torque Therapeutics

Most Recent Events

18 Nov 2019 New trial record
08 Nov 2019 According to an Torque Therapeutics media release, the company is preparing to move into clinical trials in the latter part of 2019 and in 2020, including a combination study of Deep IL-12 and Deep IL-15 Primed T cells.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com